According to Beer et al., data from the recent ASCENT trial demonstrates that elevated C-reactive protein (CRP) levels in patients receiving docetaxel-based regimens for the treatment of hormone-refractory (also known as androgen-independent) prostate cancer is highly predictive of poor survival and a lower probability of PSA response to treatment. Perhaps a more patient-oriented way to look at this is that therefore lower levels of CRP are presumably associated with a relatively better response to treatment and longer-term survival.
Filed under: Uncategorized
